New FLT3 blocker launches in Japan first

10 October 2019

Tokyo’s Daiichi Sankyo (TYO: 4568) has launched its oral FLT3 inhibitor Vanflyta (quizartinib) in Japan.

The drug, which was approved in June 2019 for the treatment of certain people with acute myeloid leukemia (AML), is the first of seven new oncology therapies Daiichi wants to deliver to the market by 2025.

Daiichi picked up rights to the drug as part of its $410 million acquisition of Ambit Biosciences in 2014. The firm is aiming to compete in the myeloid leukemia indication with Astellas’ (TYO: 4503) Xospata (gilteritinib), among others.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK